Home
About Us
About Us

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.
News
R&D and Products
R&D and Products

Primarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases.
Investor Relations
Investor Relations

Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
Our Businesses
- NL-PHARM
- Hounland
Our Businesses

Owns Beijing Northland Biopharmaceutical Co., Ltd. and Beijing Huons Pharmaceutical Co., Ltd., which are engaged in bioengineering drugs and ophthalmic products, respectively.

Language

Call for Intentions to Cooperate on NORTHLAND's Innovative Drug Donaperminogene Seltoplasmid Ingection (Not Yet Approved)

发布时间：2025-09-04

2023-07

NORTHLAND Ophthalmic Pharmaceuticals is recruiting regional and provincial agents!

发布时间：2023-07-18

Several ophthalmic products under NORTHLAND have been officially launched. Adhering to the business philosophy of putting customers first and upholding integrity, the company is now sincerely recruiting provincial-level distributors. We look forward to collaborating with like-minded partners to jointly pursue growth and development!

2022-02

[Recruitment] Phase III Clinical Trial of Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection for the Treatment of Severe Lower Limb Ischemic Disease Grade 4 (Rest Pain) & Grade 5 (Ulceration) according to Rutherford Classification

发布时间：2022-02-23

“Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection” is a novel therapeutic biological product developed by Beijing Northland Biotechnology Co., Ltd. This product has not yet been approved for marketing in China.

2020-07

Phase III Clinical Trial for Severe Lower Limb Ischemic Disease—Recruiting Clinical Subjects

发布时间：2020-07-01

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

ADR information: Click to Download

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

Web site

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license